Ampicillin-Sulbactam for Pediatric UTI
Ampicillin-sulbactam can be used as an effective alternative to cephalosporins for treating urinary tract infections in children, particularly for first-episode UTIs in infants and young children, though it is not listed among the first-line empirical agents in current AAP guidelines.
Guideline Recommendations
The 2011 AAP guidelines for febrile UTIs in children 2-24 months 1 recommend:
First-line oral agents:
- Cephalosporins (cefixime, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin)
- Amoxicillin-clavulanate (20-40 mg/kg/day in 3 doses)
- Trimethoprim-sulfamethoxazole
Parenteral options for toxic-appearing children:
- Ceftriaxone (75 mg/kg every 24h)
- Cefotaxime (150 mg/kg/day divided every 6-8h)
- Gentamicin or tobramycin
- Piperacillin (300 mg/kg/day divided every 6-8h)
Notably, ampicillin-sulbactam is not explicitly listed in these AAP recommendations, though piperacillin (a related beta-lactam) is included.
The 2024 JAMA guidelines 2 emphasize that empirical treatment should be based on local resistance patterns and recommend ceftriaxone as the preferred IV agent for pyelonephritis requiring parenteral therapy.
FDA-Approved Indications
The FDA label 3 states that ampicillin-sulbactam safety and effectiveness have been established for pediatric patients ≥1 year old for skin and skin structure infections, but have NOT been established for intra-abdominal infections in children. Importantly, UTI is not specifically mentioned as an FDA-approved indication in pediatric patients.
Clinical Evidence Supporting Use in Pediatric UTI
Despite the lack of guideline endorsement, multiple studies demonstrate efficacy:
Most Recent and Highest Quality Study
A 2021 retrospective cohort study 4 directly compared ampicillin-sulbactam to cefotaxime in 87 infants (2-24 months) with first-episode febrile UTI:
- No significant difference in fever duration (2.0 vs 3.0 days, P=0.331)
- 100% clinical success rate in both groups
- No treatment failures or recurrences in either group, even with resistant pathogens
- Similar antibiotic susceptibilities between groups
- E. coli was the predominant pathogen
Supporting Historical Data
- 1989 study 5: 15 pediatric UTI cases treated with sulbactam/ampicillin showed 93.9% bacteriologic eradication
- 1989 Japanese study 6: 7 pediatric UTI patients showed 100% efficacy
- 1988 study 7: 25 children with UTI achieved 100% clinical cure
- 1986 study 8: 11 children with UTI caused by ampicillin-resistant organisms showed favorable response in all but 2 relapse cases
Practical Considerations
When ampicillin-sulbactam may be appropriate:
- First-episode febrile UTI in infants/young children
- Local susceptibility data shows adequate coverage
- Alternative needed due to cephalosporin allergy or shortage
- E. coli predominant pathogen with known susceptibility
Critical caveats:
- Must know local resistance patterns - susceptibility varies significantly by region 9
- The 2020 Korean study 9 showed only 61% pooled susceptibility to ampicillin-sulbactam (vs 82.8% for 3rd generation cephalosporins)
- Not appropriate for empirical therapy where local resistance exceeds 20%
- Requires 7-14 days total duration 1
- Should be adjusted based on culture and sensitivity results
Dosing: While not specified in AAP guidelines, research studies used approximately 50-75 mg/kg/day divided every 6 hours IV 5, 6, 8
Algorithm for Decision-Making
- Check local antibiogram - If ampicillin-sulbactam susceptibility >80% for E. coli → reasonable option
- If susceptibility 60-80% → consider only after culture confirmation or as second-line
- If susceptibility <60% → avoid for empirical use
- For toxic-appearing children → prefer guideline-recommended agents (ceftriaxone, cefotaxime)
- Always obtain culture and adjust therapy based on susceptibilities within 48-72 hours
The evidence suggests ampicillin-sulbactam works clinically even when guidelines don't prioritize it, but cephalosporins remain the safer empirical choice given higher susceptibility rates and stronger guideline support 2, 1.